tiprankstipranks
Teva sees FY24 adjusted EBITDA $4.7B-$5B
The Fly

Teva sees FY24 adjusted EBITDA $4.7B-$5B

Sees FY24 capital expenditures $500M. Sees FY24 free cash flow $1.7B-$2B. Says on track for FY27 targets. Guidance taken from Q3 earnings conference call.

Don't Miss our Black Friday Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App